Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines

Genes Chromosomes and Cancer

Volumn 47, Issue 7, 2008, Pages 604-613

  Noel, Elodie E ^a   Perry, Jackie ^a   Chaplin, Tracy ^a   Mao, Xueying ^a   Cazier, Jean Baptiste ^a,b   Joel, Simon P ^a   Oliver, R Tim D ^a   Young, Bryan D ^a   Lu, Yong Jie ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ARTICLE; CELL LINE; CHEMOSENSITIVITY; CHEMOTHERAPY; CHROMOSOME; CHROMOSOME LOSS; CONTROLLED STUDY; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENOMICS; GENOTYPE; GERM CELL TUMOR; HETEROZYGOSITY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICROARRAY ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 44349135036     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20564     Document Type: Article

References (46)

1. Adami HO, Bergstrom R, Mohner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Ziegler H, Rahu M, Gurevicius R, Stengrevics A. 1994. Testicular cancer in nine northern European countries. Int J Cancer 59:33-38.
2. Baron BW, Zeleznik-Le N, Baron MJ, Theisler C, Huo D, Krasowski MD, Thirman MJ, Baron RM, Baron JM. 2007. Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas. Proc Natl Acad Sci USA 104:7449-7454.
3. Benachenhou N, Labuda D, Sinnett D. 1998. Allelic instability of TBP gene in replication error positive tumors. Int J Cancer 78:525-526.
4. Bignold LP, Coghlan BL, Jersmann HP. 2006.Cancer morphology, carcinogenesis and genetic instability: a background. Exs:1-24.
5. Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS. 2007. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 26:683-700.
6. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. 1998. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br J Cancer 77:1562-1567.
7. Coleman WB, Tsongalis GJ. 2006.Molecular mechanisms of human carcinogenesis. EXS 321-349.
8. di Pietro A, Vries EG, Gietema JA, Spierings DC, de Jong S. 2005. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours. Int J Biochem Cell Biol 37:2437-2456.
9. Fukuhara H, Maruyama T, Nomura S, Oshimura M, Kitamura T, Sekiya T, Murakami Y. 2001. Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers. Oncogene 20:314-319.
10. Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627.
11. He X, He L, Hannon GJ. 2007. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67:11099-11101.
12. Hermeking H. 2007. p53 enters the microRNA world. Cancer Cell 12:414-418.
13. Hiorns LR, Seckl MJ, Paradinas F, Sharp SY, Skelton LA, Brunstrom G, Newlands ES, Kelland LR, Leyland-Jones B. 1999. A molecular cytogenetic approach to studying platinum resistance. J Inorg Biochem 77:95-104.
14. Houldsworth J, Korkola JE, Bosl GJ, Chaganti RS. 2006. Biology and genetics of adult male germ cell tumors. J Clin Oncol 24:5512-5518.
15. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RS. 1998. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16:2345-2349.
16. Johnson SW, Stevenson JP, O'Dwyer PJ. 2001. Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, pp. 376-388.
17. Kartalou M, Essigmann JM. 2001. Mechanisms of resistance to cisplatin. Mutat Res 478:23-43.
18. Kelland L. 2007. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584.
19. Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LH. 2002. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20:1551-1561.
20. Kim M, Park Y, Kim O, Lee G, Chung E, Sung Y, Kim J, Han I, Sohn Y. 2003. Gene expression profiles related with overcoming cisplatin resistance in human cancer cell lines. Cancer therapy 1:21-29.
21. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. 1997. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70:551-555.
22. Kollmannsberger C, Nichols C, Bokemeyer C. 2006. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 106:1217-1226.
23. Kon H, Sonoda Y, Kumabe T, Yoshimoto T, Sekiya T, Murakami Y. 1998. Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas. Oncogene 16:257-263.
24. Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, Bosl GJ, Chaganti RS, Murty W. 2002. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer 1:8.
25. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, Assaad AM, Mansukhani M, Reuter VE, Bosl GJ, Chaganti RS, Murty VV. 2004. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 3:16.
26. Leyland-Jones B, Kelland LR, Harrap KR, Hiorns LR. 1999. Genomic imbalances associated with acquired resistance to platinum analogues. Am J Pathol 155:77-84.
27. Looijenga LH, Zafarana G, Grygalewicz B, Summersgill B, Debiec-Rychter M, Veltman J, Schoenmakers EF, Rodriguez S, Jafer O, Clark J, van Kessel AG, Shipley J, van Gurp RJ, Gillis AJ, Oosterhuis JW. 2003. Role of gain of 12p in germ cell tumour development. Apmis 111:161-171; Discussion 172-163.
28. Masters JR, Koberle B. 2003. Curing metastatic cancer: Lessons from testicular germ-cell tumours. Nat Rev Cancer 3:517-525.
29. Mayer F, Gillis AJ, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LH. 2002. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62:2758-2760.
30. Mayer F, Honecker F, Looijenga LH, Bokemeyer C. 2003a. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 14:825-832.
31. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, Bokemeyer C. 2003b. Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9:767-773.
32. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. 2005. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 65:8085-8089.
33. Nouri A, Oliver R. 1997. Tetraploid arrest with over expressed non-mutated p53 in germ cell cancers: Relevance to their chemosensitivity and possible application in non germ cell cancers. Int J Oncol 11:1167-1371.
34. Oliver RT, Shamash J, Berney DM. 2002. p53 and MDM2 in germ cell cancer treatment response. J Clin Oncol 20:3928; Author reply 3928-3929.
35. Olsen AK, Lindeman B, Wiger R, Duale N, Brunborg G. 2005. How do male germ cells handle DNA damage? Toxicol Appl Pharmacol 207:521-531.
36. Oosterhuis JW, Looijenga LH. 2005. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 5:210-222.
37. Poignee M, Backsch C, Beer K, Jansen L, Wagenbach N, Stanbridge EJ, Kirchmayr R, Schneider A, Durst M. 2001. Evidence for a putative senescence gene locus within the chromosomal region 10p14-p15. Cancer Res 61:7118-7121.
38. Rao PH, Houldsworth J, Palanisamy N, Murty W, Reuter VE, Motzer RJ, Bosl GJ, Chaganti RS. 1998. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 58:4260-4263.
39. Rodriguez S, Jafer O, Goker H, Summersgill BM, Zafarana G, Gillis AJ, van Gurp RJ, Oosterhuis JW, Lu YJ, Huddart R, Cooper CS, Clark J, Looijenga LH, Shipley JM. 2003. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 22:1880-1891.
40. Schar P. 2001. Spontaneous DNA damage, genome instability, and cancer - when DNA replication escapes control. Cell 104:329-332.
41. Schenk PW, Stoop H, Bokemeyer C, Mayer F, Stoter G, Oosterhuis JW, Wiemer E, Looijenga LH, Nooter K. 2004. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia 6:297-301.
42. Spierings DC, de Vries EG, Vellenga E, de Jong S. 2003. The attractive Achilles heel of germ cell tumours: An inherent sensitivity to apoptosis-inducing stimuli. J Pathol 200:137-148.
43. Velasco A, Riquelme E, Schultz M, Wistuba, II, Villarroel L, Koh MS, Leach FS. 2004a. Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther 3:1152-1158; Discussion 1159-1161.
44. Velasco A, Riquelme E, Schultz M, Wistuba, II, Villarroel L, Pizarro J, Berlin A, Ittmann M, Koh MS, Leach FS. 2004b. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther 3:977-982.
45. Wilson C, Yang J, Strefford JC, Summersgill B, Young BD, Shipley J, Oliver T, Lu YJ. 2005. Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. Genes Chromosomes Cancer 43:211-216.
46. Wilson TR, Longley DB, Johnston PG. 2006. Chemoresistance in solid tumours. Ann Oncol 17(Suppl 10):x315-x324.